#### **Overview** Gujarat Themis Biosyn Limited (GTBL) is a specialized Indian pharmaceutical company with core expertise in **fermentation-based manufacturing** of high-value **pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs)**. Established in **1981** as a joint-sector venture between **GIIC Ltd. (Government of Gujarat)** and **Chemosyn (P) Ltd.**, GTBL has emerged as a pioneer and one of the **few indigenous manufacturers** in India with advanced fermentation capabilities. The company operates a **state-of-the-art manufacturing facility in Vapi, Gujarat**, and employs over **200 people**. GTBL leverages sustainable **aerobic bacterial fermentation technology** and is strategically positioned to address **import dependency in fermentation-derived products**, with a strong focus on **domestic growth and export expansion**. --- #### **Core Business & Product Portfolio** GTBL operates in a **single business segment**: the production of **fermentation-derived pharmaceutical intermediates and APIs**, primarily within the **rifamycin class**. **Key Products:** - **Rifamycin S**: Intermediate for **Rifampicin**, an antibiotic used in treating **tuberculosis, leprosy, and other bacterial infections**. - **Rifamycin O**: Intermediate for **Rifaximin**, used to treat **irritable bowel syndrome (IBS), traveler’s diarrhea, and hepatic encephalopathy**. **Fermentation Capacity:** - Total fermentation capacity: **up to 990 kiloliters** - **Monthly fungible production capacity** of **16,000 kilograms** across product lines --- #### **Strategic Developments (2022–2025)** 1. **Forward Integration into API Manufacturing** - GTBL has successfully launched **commercial operations at its new multi-purpose API facility** in Vapi, marking a key milestone in its **forward integration strategy**. - The facility supports the production of **Rifapentine** (a TB treatment API with potential WHO-recommended status) and other **Rifa-based APIs**. - This integration enables GTBL to **move up the value chain**, target **higher-margin products**, and cater directly to **regulated markets** like the **USA and Europe**. 2. **Expansion of Fermentation Capacity** - The company is **expanding fermentation capacity** within its existing land in Vapi to support commercialization of new molecules. - This expansion is aligned with **R&D-driven product development** and is critical for serving rising domestic and global demand. - Environmental clearance has been secured, and new infrastructure is being built to meet **strict global regulatory standards** (e.g., USFDA, EMA). 3. **R&D and Innovation** - A **state-of-the-art R&D center** is being rolled out in phases. **Phase 1 was commissioned in August 2025**. - The R&D unit operates to **international standards** and focuses on: - Developing **new fermentation-based molecules** - Exploring new therapeutic applications for existing products - Advancing **semi-synthetic drug development** (fermentation + chemical synthesis) - The company is internally developing **6+ new fermentation-based molecules**, with commercialization planned in sync with CAPEX project completion. 4. **Capital Expenditure & Growth Strategy** - GTBL is executing a **multi-year, ₹200+ crore capex program** focused on: - Expanding R&D capabilities - Building API manufacturing infrastructure - Increasing fermentation capacity - The strategy emphasizes **organic growth** through **capacity expansion**, **technology advancement**, and **geographical diversification**, while remaining open to **inorganic opportunities (M&A)** in the **specialty chemicals and biopharma space**. --- #### **Market Position & Competitive Edge** - GTBL is **one of only a few Indian companies** with **end-to-end fermentation technology expertise**, giving it a **first-mover advantage** in a technically challenging domain. - The company differentiates itself through: - **Superior execution, quality, and on-time delivery** - **Robust in-house technical know-how** in strain development and fermentation optimization - **Strong customer relationships** and a **stable order book** - **Cost efficiency** and **environmentally friendly processes** - Unlike many domestic players dependent on imports (especially from China), GTBL uses **locally available raw materials** such as **vegetable waste oil**, reducing supply chain risks. --- #### **Financial Highlights (FY 2024–25)** - **Revenue**: ₹150.8 crores - **EBITDA**: ₹68.8 crores - **Profit after Tax**: ₹48.8 crores - **Growth Drivers**: - Strong demand for rifamycin intermediates - Improved operational efficiency (100% operational efficiency achieved) - Successful transition to **market-based pricing** from earlier cost-plus models - No major plant shutdowns despite seasonal power disruptions > GTBL remains **net debt-free** with a conservative financial structure, enabling robust investment in long-term strategic projects. --- #### **Strategic Shifts & Focus Areas** - **Withdrawal from Merger with Themis Medicare Ltd. (June 2025)**: GTBL has abandoned the proposed amalgamation to **focus exclusively on its core fermentation-based business**, ensuring strategic clarity and capital allocation efficiency. - **Commercial-Only Focus**: New API products are being developed for **commercial (B2B) markets**, not government tenders—except in areas like TB where public programs dominate. - **Geographical Expansion**: While the company currently produces in Vapi, it is evaluating **new manufacturing footprints within India** to meet regulatory and capacity needs. --- #### **Sustainability & Compliance** - GTBL uses an **eco-friendly aerobic fermentation process**, supporting sustainable manufacturing. - All new facilities are designed to comply with **global regulatory standards**, essential for exporting to **US, EU, and other regulated markets**. - A **new GMP-compliant warehouse** has been constructed to support future compliance and logistics.